Robert H. Hyland, DPhil

AlloVir
Chapel Hill, North Carolina, United States

Gilead Sciences, Inc (Shareholder, Other Financial or Material Support, Employee during the conduct of this trial)

Presentation(s):

• LB1 - Remdesivir for the Treatment of High-Risk Non-Hospitalized Individuals With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial

  Thursday, September 30, 2021
  5:15 PM - 5:30 PM EDT